CTSS and cancer: This frailty can be targeted by lysosomotropic compound that may have an antitumor effect preferentially killing the more sensitive cancer cells by inducing dysregulation of lysosomal lipid metabolism and LMP with release into the cytosol of cathepsins, potent inducers of cell death (17, 75, 76).